For cancers derived from the digestive system, a Phase I/Ib Study evaluating AZD9150 (a STAT3 inhibitor, ISIS-STAT3Rx) in Patients with Advanced/Metastatic Hepatocellular Carcinoma (NCT01839604, http://www.clinicaltrials.gov/, Table 4) is in process. The gene discussed is STAT3; the disease is cancer.